Stock DNA
Pharmaceuticals & Biotechnology
CNY 15,568 Million (Large Cap)
15.00
NA
4.85%
-0.43
22.50%
3.87
Revenue and Profits:
Net Sales:
1,286 Million
(Quarterly Results - Dec 2025)
Net Profit:
245 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
4.42%
0%
4.42%
6 Months
18.93%
0%
18.93%
1 Year
15.26%
0%
15.26%
2 Years
14.34%
0%
14.34%
3 Years
40.08%
0%
40.08%
4 Years
103.15%
0%
103.15%
5 Years
141.65%
0%
141.65%
Jiangzhong Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
11.68%
EBIT Growth (5y)
15.28%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.41
Sales to Capital Employed (avg)
1.06
Tax Ratio
15.82%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
43.69%
ROE (avg)
16.29%
Valuation key factors
Factor
Value
P/E Ratio
15
Industry P/E
Price to Book Value
3.51
EV to EBIT
13.18
EV to EBITDA
11.41
EV to Capital Employed
4.80
EV to Sales
2.88
PEG Ratio
1.23
Dividend Yield
5.46%
ROCE (Latest)
36.47%
ROE (Latest)
22.88%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ
Dec'25
Sep'25
Change(%)
Net Sales
1,286.30
792.10
62.39%
Operating Profit (PBDIT) excl Other Income
262.80
232.80
12.89%
Interest
1.10
0.20
450.00%
Exceptional Items
4.10
0.40
925.00%
Consolidate Net Profit
244.90
183.30
33.61%
Operating Profit Margin (Excl OI)
173.90%
244.50%
-7.06%
USD in Million.
Net Sales
QoQ Growth in quarter ended Dec 2025 is 62.39% vs -17.23% in Sep 2025
Consolidated Net Profit
QoQ Growth in quarter ended Dec 2025 is 33.61% vs -27.46% in Sep 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
4,184.60
4,402.40
-4.95%
Operating Profit (PBDIT) excl Other Income
1,172.50
1,035.00
13.29%
Interest
2.60
2.20
18.18%
Exceptional Items
33.50
-5.80
677.59%
Consolidate Net Profit
987.60
860.50
14.77%
Operating Profit Margin (Excl OI)
243.80%
203.80%
4.00%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is -4.95% vs -2.56% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 14.77% vs 9.34% in Dec 2024
About Jiangzhong Pharmaceutical Co., Ltd. 
Jiangzhong Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






